Bodhecom and RuiPu Bio Forge Global Strategic Partnership to Launch BT-201, the World’s First Treg-Mechanism Topical Drug, Pioneering a New Era in Immune Therapy

(Source: Arterial New Medicine)

On October 27, 2025, just as the 2025 Nobel Prize in Physiology or Medicine (recognizing the discovery of the regulatory T cell/Treg peripheral immune tolerance mechanism) had been announced, Benerhera, a company focused on innovative Treg immunotherapy,Benerhera (Shaoxing) Biotechnology Co., Ltd.(hereinafter referred to as“Benerhera”) and the leading company in China's animal health fieldRuiPu BioJoint Stock Company(hereinafter referred to as“RuiPu Bio”) officially announced the establishment of a strategic partnership.

Both parties will focus on Benerhera's core pipeline BT-201 (the world’s first topical small-molecule formulation based on the Treg mechanism) and jointly advance its global research, registration, and commercialization in the field of animal health. The product is based on a novel mechanism of core immunosuppression by regulatory T cells (Treg), originally discovered by Benerhera's founding team, marking the first time cutting-edge immunology science has been translated into practical therapeutic applications. It provides an innovative solution for skin inflammatory diseases caused by autoimmune responses.

This collaboration not only achieved a breakthrough in the industrial transformation of cutting-edge Treg immunology but also provided a disruptive treatment solution for autoimmune skin inflammatory diseases, marking China's original immunotherapy as reaching a globally leading position in cross-species application.

01.

Scientific Originality: Mechanistic Breakthrough Based on Nobel Prize Achievements

The 2025 Nobel Prize in Physiology or Medicine has been awarded for "the discovery of regulatory T cells and their central role in peripheral immune tolerance."”The three scientists, whose achievements have laid the foundation for understanding the pathogenesis of autoimmune diseases. The founding team of Benerhera has深耕十余年 on this basis, achieving a critical leap from basic research to application transformation - systematically elucidating the molecular mechanism of Treg cells' immunosuppressive function for the first time from the core环节 of cell adhesion interactions, and successfully identifying key signaling pathway regulatory targets.

This original discovery reveals that Treg cells can directly block the antigen presentation process of dendritic cells (DC cells, key antigen-presenting cells in the immune system) to effector T cells by enhancing specific adhesion with DC cells, thereby suppressing the initiation of inflammatory responses at the source. The elucidation of this mechanism provides a foundation for the development of "precise targeting and localized regulation."”The immunotherapy drugs provided a new theoretical basis, completely changing the traditional immunotherapy's reliance on "broad-spectrum inhibition.”Or "single cytokine blockade”Limitations.

02.

Dual Technological Breakthroughs: Building a Globally Leading Treatment System

■ 1. Mechanism Innovation: Precise Reconstruction of Immune Balance

BT-201 was developed based on the aforementioned original mechanism. By targeting and modulating key signaling pathways, it can induce the conversion of pro-inflammatory T cells in the body into Treg-like cells with immunoregulatory functions, achieving "a transformation from pathogenic cells to regulatory cells."”Phenotypic remodeling. Compared with traditional therapies, this mechanism can accurately restore local immune balance at the lesion site, avoiding both the systemic immune function decline caused by broad-spectrum immunosuppressants and the limited efficacy of single-target drugs.

■ 2. Targeted Design: The Optimal Solution Balancing Efficacy and Safety

As the world's first small-molecule drug targeting the core immunosuppressive pathway of Tregs, BT-201 exhibits extremely high target specificity. Preclinical studies have shown that the drug can specifically accumulate at skin inflammatory lesions, exerting its therapeutic effects by modulating the local immune microenvironment without significantly affecting the body's normal immune defense functions, ensuring treatment safety at the molecular level.

03.

Strategic Cooperation: The Pinnacle of Synergy Between Technology and Industry, Setting New Heights in the Industry

This collaboration is a key milestone for Benerhera in transforming original scientific research achievements into industrial applications, and it also represents a significant advancement in China's animal health sector, combining "original technology + commercialization capabilities."”A model of collaborative innovation. Both parties will integrate core advantageous resources to accelerate the global industrialization process of BT-201.

The project sets up a ladder-style milestone covering key nodes such as preclinical research, clinical trials, global registration, and market launch. The total amount of the collaboration is expected to set a new historical high for technology licensing transactions in China's animal health sector, fully demonstrating the market's high recognition of the innovative value of the Treg mechanism.

04.

Industry Innovation: Defining New Standards for Animal Immunotherapy

Currently, the treatment of autoimmune skin diseases still relies on traditional drugs such as glucocorticoids, calcineurin inhibitors, and JAK inhibitors, which commonly present challenges such as excessive immunosuppression, high incidence of drug resistance, high recurrence rates, and hepatorenal toxicity. The advent of BT-201 has completely changed this situation, with its "localized induction of Treg-like cells."”The core mechanism can achieve "immune suppression + tissue repair".”The dual effect, with three core competitive advantages:

● Safety Breakthrough: Topical application avoids systemic side effects, significantly reducing the burden on the liver and kidneys;

● Enhanced efficacy: Targeted induction of Treg-like cells enables long-term regulation of the local immune microenvironment, significantly reducing the recurrence rate of skin diseases;

● Potential of Co-research for Humans and Pets: Optimized based on the human Treg mechanism, with a scientific foundation for reversely promoting the upgrade of human immunotherapy drugs.

Industry analysis data shows that the global pet immunotherapy drug market is growing rapidly at a compound annual growth rate of 15.2%, and is expected to exceed USD 3 billion by 2030. Local immunotherapy drugs based on the Treg mechanism remain a blue ocean market. With its original mechanism and clinical advantages, BT-201 is expected to become a global benchmark product in this field.

05.

Authoritative Recognition: Jointly Acknowledged by Scientists and Industry Experts

Professor Yan Shi, founder of Benerhera (Ph.D. supervisor at Tsinghua University's Institute of Immunology, discoverer of the core immunosuppressive mechanism of Tregs)"We have spent more than ten years as a team to reveal, for the first time from the perspective of cellular mechanics, the 'brake' mechanism of Treg in inflammatory responses. This not only deepens the Nobel Prize-winning findings but also opens up a new direction for the treatment of autoimmune diseases. The translational application of BT-201 in animal health provides a replicable successful model for the industrialization of original basic research."”

Ailing Liu, Dean of the Raybiotech Drug Research Institute"Treg cell technology represents a major breakthrough, precisely addressing the pain points of traditional pet immunotherapy. Animal experimental results show that BT-201 has demonstrated remarkable efficacy, enabling localized precision treatment and meeting the clinical need for both accuracy and safety. This indicates that the entire industry is poised to move from symptomatic suppression to a new phase of precision repair."

Professor Jiahao Lin from China Agricultural UniversityComment: "Traditional pet skin inflammation treatments have long been limited by drug side effects and efficacy bottlenecks. The innovative mechanism of BT-201 provides a scientific solution to address hormone dependency and the toxic side effects of immunosuppressants. This collaboration achieves precise alignment between cutting-edge immunology science and animal clinical needs, marking an important milestone for the animal pharmaceuticals industry in advancing towards precision immune therapy."”

06.

Future Outlook: Opening a New Era of Cross-Species Applications in Immunotherapy

Dr. Liu Feng, Chief Operating Officer of Benerhera"This collaboration marks a crucial leap for Benerhera from fundamental research to animal clinical trials. We firmly believe that BT-201 will redefine the treatment standards for immune diseases, offering safer and longer-lasting therapeutic options for companion animals and livestock worldwide. It will also validate the universality of the Treg mechanism in cross-species applications, providing valuable data for subsequent human drug development. Ruipu Biotech's channel advantages and global layout in the field of animal health are the core guarantees for promoting this innovative technology to benefit users globally."”

Li Shoujun, Chairman of Ringpu BioStated: "For more than 20 years, ReproBio has always been centered on innovation.Driving Force, continuously increasing R&D investment, closely monitoring breakthrough and disruptive technologies in the global biomedicine field, and deeply cultivating the integration of industry, academia, and research for innovative development. BT-201 represents one of the top innovative directions we have been focusing on for a long time. Ruipu Bio will fully integrate its core advantages in the R&D system, manufacturing, and global channel layout to jointly accelerate the global commercialization process of BT-201 with Benerhera. This will allow China-originated immunotherapy to benefit pets worldwide while leading the industry into a new era of precision immune treatment through technological integration."

About Benerhera

Benerhera (Shaoxing) Biotechnology Co., Ltd. was founded in December 2021 by Professor Yan Shi's team from the Institute of Immunology at Tsinghua University. It is a biopharmaceutical company focused on innovative Treg immunotherapy. The company addresses unmet clinical needs in autoimmune diseases, allergies, and inflammatory responses, and is committed to developing world-leading small molecule and cell therapy products. The core R&D team consists of immunology experts from top institutions such as Tsinghua University in China, the University of Toronto in Canada, the University of Calgary in Canada, and Leiden University in the Netherlands. The company has applied for more than 20 core patents and established a complete R&D system ranging from mechanistic research to product development.

About Repro Biotech

Ringpu Biology, founded in 1998 (stock code: 300119), is a leading enterprise in China's animal health industry and was listed on the ChiNext Board of the Shenzhen Stock Exchange in 2010. The company has over 20 subsidiaries and operates 84 large-scale production lines. Committed to innovation-driven development, Ringpu Biology has achieved remarkable success in technology research and development, establishing platforms such as the "National Enterprise Technology Center," the "Key Laboratory of Biological Veterinary Drug Innovation of the Ministry of Agriculture," and the "Tianjin AI Drug Research and Development Key Laboratory." To date, the company has obtained 118 New Veterinary Drug Registration Certificates and has been awarded the National Science and Technology Progress Award (Second Prize) twice. Its business covers areas such as chemical drugs, biological products, traditional Chinese veterinary medicine, pharmaceutical raw materials, and functional feed additives, widely used in pets, poultry, livestock, and aquaculture, providing comprehensive protection for animal health.